These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, Cassese S, Laugwitz KL, Schunkert H, Kastrati A, Byrne RA, ISAR-TEST 4 (Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents) Investigators. Circulation; 2019 Jan 15; 139(3):325-333. PubMed ID: 30586724 [Abstract] [Full Text] [Related]
12. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes. Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R, BIOFLOW V Investigators. JACC Cardiovasc Interv; 2022 Sep 26; 15(18):1852-1860. PubMed ID: 36137689 [Abstract] [Full Text] [Related]
15. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. Kandzari DE, Koolen JJ, Doros G, Massaro JJ, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R, BIOFLOW V Investigators. J Am Coll Cardiol; 2018 Dec 25; 72(25):3287-3297. PubMed ID: 30257191 [Abstract] [Full Text] [Related]
16. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB, TARGET I Investigators. EuroIntervention; 2013 May 20; 9(1):75-83. PubMed ID: 23685298 [Abstract] [Full Text] [Related]
18. Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial. Xu B, Zhang YJ, Sun ZW, Qiao SB, Chen SL, Zhang RY, Pan DR, Pang S, Zhang Q, Xu L, Yang YJ, Leon MB, Gao RL. Int J Cardiovasc Imaging; 2015 Dec 20; 31(8):1489-96. PubMed ID: 26208685 [Abstract] [Full Text] [Related]